Guardian

Superbugs could kill millions more and cost $2tn a year by 2050, models show

BioMed Central

The neglected model validation of antimicrobial resistance transmission models  a systematic review - Antimicrobial Resistance & Infection Control

BMJ Global Health

The global economic burden of antibiotic-resistant infections and the potential impact of bacterial vaccines: a modelling study

Observer (NY)

Budget cuts close UK body tackling antimicrobial resistance

Congress rolls back $9 billion in public media funding and foreign aid

GOV.UK

UKHSA launches campaign to tackle misconceptions on antibiotics

NCBI

Response to antimicrobial resistance in South-East Asia Region

World Economic Forum

We must redefine the private sectors role in global health

Metaculus

Antibiotic-Resistant Infection Deaths x2 2026

The Telegraph

Major UK project to tackle AMR closed by aid cuts

<h2>Editor's Note</h2>

Antimicrobial resistance (AMR) could cause global annual GDP losses of $1.7 trillion by 2050, according to modeling by the Center for Global Development. The U.S. faces $295.7 billion in losses, the EU $187 billion, and the U.K. $58.6 billion.

Cgdev

Antimicrobial resistance (AMR) could cause global annual GDP losses of $1.7 trillion by 2050, according to modeling by the Center for Global Development. The U.S. faces $295.7 billion in losses, the EU $187 billion, and the U.K. $58.6 billion.

Deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the U.S. and 184,000 in the U.K. predicted to die annually from antibiotic-resistant infections. Meanwhile, global health costs for treating AMR are projected to increase by $176 billion annually.

Deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the U.S. and 184,000 in the U.K. predicted to die annually from antibiotic-resistant infections. Meanwhile, global health costs for treating AMR are projected to increase by $176 billion annually.

In low- and lower-middle-income countries, health care costs could rise to $159 billion under business-as-usual scenarios. If resistance rates increased at the rate of the bottom 15% of countries, AMR health costs would increase to $325 billion, and the global economy would be $1.7 trillion smaller in 2050.

In low- and lower-middle-income countries, health care costs could rise to $159 billion under business-as-usual scenarios. If resistance rates increased at the rate of the bottom 15% of countries, AMR health costs would increase to $325 billion, and the global economy would be $1.7 trillion smaller in 2050.

Mathematical models studying AMR transmission primarily focus on high-income regions, such as Europe and North America, where surveillance data are more readily available, despite Sub-Saharan Africa carrying the highest burden of AMR.

Mathematical models studying AMR transmission primarily focus on high-income regions, such as Europe and North America, where surveillance data are more readily available, despite Sub-Saharan Africa carrying the highest burden of AMR.

Antibiotic-resistant bacteria were associated with nearly $700 billion in hospital costs globally in 2019, while productivity losses exceeded $193 billion due to excess deaths linked to antibiotic resistance.

Antibiotic-resistant bacteria were associated with nearly $700 billion in hospital costs globally in 2019, while productivity losses exceeded $193 billion due to excess deaths linked to antibiotic resistance.

Vaccines targeting antibiotic-resistant infections could prevent 30% of hospital costs (around $200 billion) and 40% of productivity losses (almost $80 billion) under hypothetical vaccine scenarios. Vaccines against S. aureus, E. coli, and K. pneumoniae would avert the most hospital costs, totaling $169 billion, and $44 billion in productivity losses globally.

Vaccines targeting antibiotic-resistant infections could prevent 30% of hospital costs (around $200 billion) and 40% of productivity losses (almost $80 billion) under hypothetical vaccine scenarios. Vaccines against S. aureus, E. coli, and K. pneumoniae would avert the most hospital costs, totaling $169 billion, and $44 billion in productivity losses globally.

Guardian #4399

BioMed Central #

BMJ Global Health #

Observer (NY) #

NPR #8551

GOV.UK #

NCBI #

World Economic Forum #

Metaculus #

The Telegraph #

Global health costs for treating antimicrobial resistance could increase by $176 billion annually, while antibiotic-resistant bacteria were associated with almost $700 billion in hospital costs globally in 2019. Productivity losses exceeded $193 billion due to excess deaths associated with antibiotic resistance, with resistant infections roughly twice as expensive to treat as those responsive to antibiotics.</span

Global health costs for treating antimicrobial resistance could increase by $176 billion annually, while antibiotic-resistant bacteria were associated with almost $700 billion in hospital costs globally in 2019. Productivity losses exceeded $193 billion due to excess deaths associated with antibiotic resistance, with resistant infections roughly twice as expensive to treat as those responsive to antibiotics.

Low- and lower-middle-income countries bear the heaviest burden of antimicrobial resistance, with health care costs increasing by $66 billion currently and projected to rise to $159 billion under business-as-usual scenarios. If resistance rates increased at the rate of the bottom 15% of countries, AMR health costs would rise to $325 billion and the global economy would be $1.7 trillion smaller in 2050.</span

Low- and lower-middle-income countries bear the heaviest burden of antimicrobial resistance, with health care costs increasing by $66 billion currently and projected to rise to $159 billion under business-as-usual scenarios. If resistance rates increased at the rate of the bottom 15% of countries, AMR health costs would rise to $325 billion and the global economy would be $1.7 trillion smaller in 2050.

Vaccines targeting antibiotic-resistant infections could prevent substantial economic losses, with 30% of hospital costs (around $200 billion) and 40% of productivity losses (almost $80 billion) potentially averted under hypothetical vaccine scenarios. Vaccines against S. aureus, E. coli and K. pneumoniae would avert the most hospital costs at $169 billion total and $44 billion in productivity losses globally.</span

Vaccines targeting antibiotic-resistant infections could prevent substantial economic losses, with 30% of hospital costs (around $200 billion) and 40% of productivity losses (almost $80 billion) potentially averted under hypothetical vaccine scenarios. Vaccines against S. aureus, E. coli and K. pneumoniae would avert the most hospital costs at $169 billion total and $44 billion in productivity losses globally.

The UK government has eliminated funding for the $265 million Fleming Fund, which supports antimicrobial resistance surveillance in 25 countries across Africa and Asia, as part of aid budget cuts from 0.5% to 0.3% of gross national income. The US Congress approved $9 billion in cuts to foreign aid programs, with the Trump administration confirming these reductions amid broader international aid budget decreases.</span

The UK government has eliminated funding for the $265 million Fleming Fund, which supports antimicrobial resistance surveillance in 25 countries across Africa and Asia, as part of aid budget cuts from 0.5% to 0.3% of gross national income. The US Congress approved $9 billion in cuts to foreign aid programs, with the Trump administration confirming these reductions amid broader international aid budget decreases.

Mathematical models studying AMR transmission primarily focus on high-income regions like Europe and North America where surveillance data are more accessible, despite Sub-Saharan Africa carrying the highest AMR burden. Key pathogens contributing to AMR-associated deaths include E. coli, S. aureus, and K. pneumoniae, with significant modeling gaps evident for community-acquired infections and secondary bacterial infections following viral infections.</span

Mathematical models studying AMR transmission primarily focus on high-income regions like Europe and North America where surveillance data are more accessible, despite Sub-Saharan Africa carrying the highest AMR burden. Key pathogens contributing to AMR-associated deaths include E. coli, S. aureus, and K. pneumoniae, with significant modeling gaps evident for community-acquired infections and secondary bacterial infections following viral infections.

Fiscal responsibility demands tough choices, and domestic priorities must come first during challenging economic times. The partnerships and expertise from programs like the Fleming Fund will continue even without direct funding, while countries can develop their own surveillance capabilities. Defense spending increases are essential for national security, and the private sector can step up to fill gaps in global health initiatives.

Fiscal responsibility demands tough choices, and domestic priorities must come first during challenging economic times. The partnerships and expertise from programs like the Fleming Fund will continue even without direct funding, while countries can develop their own surveillance capabilities. Defense spending increases are essential for national security, and the private sector can step up to fill gaps in global health initiatives.

Superbugs Could Cost Global Economy $2 Trillion by 2050

Health

Diseases & conditions

United Kingdom

United States of America

Federal aid cuts are dangerously shortsighted, given that antimicrobial resistance poses a significant threat to global security. The economic modeling shows that every dollar invested in AMR prevention delivers a 28:1 return, making these programs among the most cost-effective interventions available. Cutting international AMR surveillance now virtually guarantees higher resistance rates worldwide, ultimately costing developed nations far more in the long run.

Federal aid cuts are dangerously shortsighted, given that antimicrobial resistance poses a significant threat to global security. The economic modeling shows that every dollar invested in AMR prevention delivers a 28:1 return, making these programs among the most cost-effective interventions available. Cutting international AMR surveillance now virtually guarantees higher resistance rates worldwide, ultimately costing developed nations far more in the long run.

Fiscal responsibility requires tough choices, and domestic priorities must take precedence during challenging economic times. The partnerships and expertise from programs like the Fleming Fund will continue even without direct funding, allowing countries to develop their own surveillance capabilities. Defense spending increases are essential for national security, and the private sector can play a crucial role in filling gaps in global health initiatives.

Fiscal responsibility requires tough choices, and domestic priorities must take precedence during challenging economic times. The partnerships and expertise from programs like the Fleming Fund will continue even without direct funding, allowing countries to develop their own surveillance capabilities. Defense spending increases are essential for national security, and the private sector can play a crucial role in filling gaps in global health initiatives.

There's an 8% chance that the number of deaths from antibiotic-resistant infections per year will double by Dec. 31, 2025, according to the Metaculus prediction community.

There's an 8% chance that the number of deaths from antibiotic-resistant infections per year will double by Dec. 31, 2025, according to the Metaculus prediction community.

Study: Superbugs Could Cost Global Economy $1.7T by 2050

Study: Superbugs Could Cost Global Economy $21.7T Trillion by 2050

The Spin

Metaculus Prediction

Editor's Note

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters